RxDoctor Payments Data

Melissa Hoehler

Family · Louisville, KYNPI 1891015533

Payments from drug & device makers

$4,571in general payments, 2019–2025

Across 175 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Saluda Medical Americas, Inc.$782
  • Collegium Pharmaceutical, Inc.$613
  • AbbVie$370
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$343
  • GRT US Holding, Inc.$175
  • plus $853 from 18 others

What the payments were for

  • Travel & lodging$70415%
  • Food & beverage$3,75982%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,571 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$23,008
Medicare patients
153
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl28$22,707
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen514$10,014
Gabapentin553$5,684
Pregabalin125$4,856
Buprenorphine15$4,670
Lidocaine28$2,867
Tizanidine Hcl278$1,311
Diclofenac Sodium97$1,182
Cyclobenzaprine Hcl262$1,153
Tramadol Hcl126$1,062
Amitriptyline Hcl50$787
Baclofen119$747
Duloxetine Hcl22$585
Diclofenac Potassium24$568
Ibuprofen45$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$613$22,70728 claims
Hikma Pharmaceuticals USABuprenorphine$17$4,67015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →